773PD - Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

Date 09 October 2016
Event ESMO 2016 Congress
Session Genitourinary tumours, non-prostate
Topics Renal Cell Cancer
Presenter Michael Atkins
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors M.B. Atkins1, E.R. Plimack2, I. Puzanov3, M.N. Fishman4, D. McDermott5, D.C. Cho6, U. Vaishampayan7, S. George8, T. Olencki9, J. Tarazi10, B. Rosbrook10, K. Fernandez11, S. Keefe12, T.K. Choueiri13
  • 1Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 20057 - Washington/US
  • 2Department Of Hematology/oncology, Fox Chase Cancer Center, PA 19111-2497 - Philadelphia/US
  • 3Hematology Oncology, Vanderbilt Ingram Cancer Center, 37232 - Nashville/US
  • 4Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa/US
  • 5Division Of Hematology/oncology, Beth Israel Deaconess Med. Center, 02215 - Boston/US
  • 6Medical Oncology, NYU Langone Medical Center, 10016 - New York/US
  • 7Medical Oncology, Karmanos Cancer Institute, Detroit/US
  • 8Department Of Medicine, Roswell Park Cancer Institute, 14263 - Buffalo/US
  • 9Medical Oncology, Ohio State Univ Medical Center, 43210 - Columbus/US
  • 10Oncology, Pfizer Inc, San Diego/US
  • 11Onclology, Pfizer, Cambridge/US
  • 12Oncology, Merck & Co., Inc., Kenilworth/US
  • 13Medical Oncology, Dana-Farber cancer Institute, Boston, MA/US



Axitinib, an inhibitor of vascular endothelial growth factor receptors, is approved for 2nd-line treatment of aRCC. Pembrolizumab is a humanized monoclonal antibody that blocks binding of the immune-checkpoint receptor programmed death-1 (PD-1) to its ligands (PD-L1/2). Here we report preliminary safety and efficacy results from an ongoing phase Ib study of axitinib plus pembrolizumab in treatment-naïve pts with aRCC.


Pts included have clear-cell aRCC with primary tumor resected, ≥1 measureable lesion, ECOG performance status 0-1, controlled hypertension, and no prior systemic therapy for aRCC. Axitinib is administered orally 5 mg twice daily; pembrolizumab is administered 2 mg/kg intravenously on Day 1 of each 3-week cycle. Tumors are assessed, using RECIST v1.1, at baseline, week 12, and every 6 weeks thereafter. Study endpoints include adverse events (AEs), other safety measures and tumor response. IHC-based assay was used to stain tumor cells for PD-L1 expression.


As of March 1, 2016, 52 pts (79% male; 87% white; mean age 61 years) were enrolled. Eleven (21.2%) pts discontinued both treatments: disease progression (n = 4); treatment-emergent AEs (n = 6; diarrhea, headache/joint pain, fatigue/joint pain, colitis/hepatitis, aggravated rheumatoid arthritis/psoriasis, and drug-induced liver injury); and other (n = 1). Thirty-five (67.3%) pts had objective response: 2 had complete response and 33 had partial responses; 11 pts had stable disease. For the 11 pts enrolled in the dose finding phase, 7 remained progression free at 11 months and the median PFS is not yet mature. Ten pts tested positive for PD-L1. Most common (>2 pts) grade 3 AEs included hypertension (n = 10), diarrhea, headache, hyponatraemia, alanine aminotransferase (ALT) increased, and aspartate aminotransferase (AST) increased (n = 3 each). Grade 4 AEs included dyspnea and hyperuricaemia (n = 1 each). Immune-related ≥grade 3 AEs included ALT and AST (n = 2 each), and diarrhea and colitis (n = 1 each).


This preliminary analysis indicates axitinib plus pembrolizumab is well tolerated and exhibits antitumor activity in treatment-naïve pts with aRCC.

Clinical trial identification


Legal entity responsible for the study

Pfizer Inc


Pfizer Inc


M.B. Atkins: declares receiving fees for consulting BMS, Pfizer, Novartis, Genentech-Roche, Merck, Amgen, Nektar, Eisai, AstraZeneca, GlaxoSmithKline, Peleton, and Acceleron. E.R. Plimack: consulting fees from Merck, GlaxoSmithKline, Pfizer, Bristol-Myers SquibbNovartis, Acceleron and Genentech/Roche, and grant support to her institution from Bristol-Myers Squibb, AstraZeneca, Peloton, Merck, GlaxoSmithKline, Acceleron, and Pfizer. M.N. Fishman: research funding from Amgen, Altor Biosciences, AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, GlaxoSmithKline, Merck, and Pfizer; speakers bureaus from Bayer, Exelixis, GlaxoSmithKline, Novartis, Pfizer, and Prometheus. D. McDermott: declares receiving fees for consulting BMS, Pfizer, Novartis, Genentech-Roche, Merck, and Exelixis. D.C. Cho: declares receiving fees for consulting from Pfizer, Genentech, Prometheus, Bristol-Meyers Squibb, and Exelixis. U. Vaishampayan: Consulting, honoraria and research support from Pfizer Inc and research support from Merck Inc. S. George: fees for consulting and advisory boards from Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, Bayer, Sanofi-Aventis, Astellas, Xcenda, and Onclive, and grant support from Bristol-Myers Squibb, Novartis, Bayer, Pfizer, Acceleron, Merck, and Agensys. J. Tarazi: an employee of and own stock in Pfizer. B. Rosbrook: an employee of and own stock in Pfizer. K. Fernandez: an employee of and own stock in Pfizer. S. Keefe: an employee of Merck & Co., Inc. T. Choueiri: fees for consulting, advisory boards: GSK, Novartis, Pfizer, Merck, AstraZeneca, Bayer, Prometheus; grant support through his institution: Bristol-Myers Squibb, GSK, Novartis, Exelixis, Pfizer, Merck, Roche, AstraZeneca, TRACON, Peloton. All other authors have declared no conflicts of interest.